Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Hybridoma
|
October 1, 1993
Tumor cell vaccination and IL-2 therapy
T Ahlert
Cancer Research
|
September 15, 1990
Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns
T Ahlert, V Schirrmacher
Gynecologic Oncology
|
August 1, 1989
Human monoclonal antibodies directed against ovarian carcinoma
M Werner, T Ahlert, G Bastert
International Journal of Oncology
|
April 11, 2001
Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects
V Schirrmacher, A Griesbach, T Ahlert
International Journal of Cancer
|
April 15, 1986
Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects
R Heicappell, V Schirrmacher, P von Hoegen, et al.
Gene Therapy
|
May 26, 1999
Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus
V Schirrmacher, C Haas, R Bonifer, et al.
International Journal of Cancer
|
March 12, 1998
Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer
A Hoos, H H Hepp, S Kaul, et al.
Seminars in Oncology
|
December 29, 1998
Immunization with virus-modified tumor cells
V Schirrmacher, T Ahlert, T Pröbstle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1997
Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer
T Ahlert, W Sauerbrei, G Bastert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 1996
Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma
D Ockert, V Schirrmacher, N Beck, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Hybridoma
|
October 1, 1993
Tumor cell vaccination and IL-2 therapy
T Ahlert
Cancer Research
|
September 15, 1990
Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns
T Ahlert, V Schirrmacher
Gynecologic Oncology
|
August 1, 1989
Human monoclonal antibodies directed against ovarian carcinoma
M Werner, T Ahlert, G Bastert
International Journal of Oncology
|
April 11, 2001
Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects
V Schirrmacher, A Griesbach, T Ahlert
International Journal of Cancer
|
April 15, 1986
Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects
R Heicappell, V Schirrmacher, P von Hoegen, et al.
Gene Therapy
|
May 26, 1999
Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus
V Schirrmacher, C Haas, R Bonifer, et al.
International Journal of Cancer
|
March 12, 1998
Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer
A Hoos, H H Hepp, S Kaul, et al.
Seminars in Oncology
|
December 29, 1998
Immunization with virus-modified tumor cells
V Schirrmacher, T Ahlert, T Pröbstle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1997
Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer
T Ahlert, W Sauerbrei, G Bastert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 1996
Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma
D Ockert, V Schirrmacher, N Beck, et al.
Page
of 1